Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 8.60
ENZ's Cash to Debt is ranked higher than
59% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.06 vs. ENZ: 8.60 )
Ranked among companies with meaningful Cash to Debt only.
ENZ' s Cash to Debt Range Over the Past 10 Years
Min: 1.91  Med: 10000.00 Max: No Debt
Current: 8.6
Equity to Asset 0.64
ENZ's Equity to Asset is ranked higher than
55% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. ENZ: 0.64 )
Ranked among companies with meaningful Equity to Asset only.
ENZ' s Equity to Asset Range Over the Past 10 Years
Min: 0.57  Med: 0.93 Max: 0.97
Current: 0.64
0.57
0.97
Interest Coverage 30.16
ENZ's Interest Coverage is ranked lower than
63% of the 93 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 166.12 vs. ENZ: 30.16 )
Ranked among companies with meaningful Interest Coverage only.
ENZ' s Interest Coverage Range Over the Past 10 Years
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: 30.16
F-Score: 6
Z-Score: 1.57
M-Score: -2.83
WACC vs ROIC
9.40%
27.68%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) 6.65
ENZ's Operating margin (%) is ranked higher than
64% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.66 vs. ENZ: 6.65 )
Ranked among companies with meaningful Operating margin (%) only.
ENZ' s Operating margin (%) Range Over the Past 10 Years
Min: -50.6  Med: -21.49 Max: -1.24
Current: 6.65
-50.6
-1.24
Net-margin (%) 6.00
ENZ's Net-margin (%) is ranked higher than
73% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.98 vs. ENZ: 6.00 )
Ranked among companies with meaningful Net-margin (%) only.
ENZ' s Net-margin (%) Range Over the Past 10 Years
Min: -39.34  Med: -21.18 Max: -2.34
Current: 6
-39.34
-2.34
ROE (%) 15.08
ENZ's ROE (%) is ranked higher than
83% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.39 vs. ENZ: 15.08 )
Ranked among companies with meaningful ROE (%) only.
ENZ' s ROE (%) Range Over the Past 10 Years
Min: -56.99  Med: -16.93 Max: -5.74
Current: 15.08
-56.99
-5.74
ROA (%) 9.09
ENZ's ROA (%) is ranked higher than
87% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.60 vs. ENZ: 9.09 )
Ranked among companies with meaningful ROA (%) only.
ENZ' s ROA (%) Range Over the Past 10 Years
Min: -43.97  Med: -15.27 Max: -3.44
Current: 9.09
-43.97
-3.44
ROC (Joel Greenblatt) (%) 56.85
ENZ's ROC (Joel Greenblatt) (%) is ranked higher than
87% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.03 vs. ENZ: 56.85 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ENZ' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -228.6  Med: -104.75 Max: -16.75
Current: 56.85
-228.6
-16.75
Revenue Growth (3Y)(%) -6.80
ENZ's Revenue Growth (3Y)(%) is ranked lower than
74% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.70 vs. ENZ: -6.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ENZ' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -9.9  Med: 4.90 Max: 24.4
Current: -6.8
-9.9
24.4
EPS Growth (3Y)(%) -63.30
ENZ's EPS Growth (3Y)(%) is ranked lower than
95% of the 110 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.10 vs. ENZ: -63.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ENZ' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -63.3  Med: 5.40 Max: 58.2
Current: -63.3
-63.3
58.2
» ENZ's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2014

ENZ Guru Trades in Q4 2014

Jim Simons 944,337 sh (+1.67%)
Dodge & Cox Sold Out
» More
Q1 2015

ENZ Guru Trades in Q1 2015

Jim Simons 1,213,643 sh (+28.52%)
» More
Q2 2015

ENZ Guru Trades in Q2 2015

Jim Simons 1,180,152 sh (-2.76%)
» More
Q3 2015

ENZ Guru Trades in Q3 2015

Jim Simons 1,113,200 sh (-5.67%)
» More
» Details

Insider Trades

Latest Guru Trades with ENZ

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 33.02
ENZ's P/E(ttm) is ranked lower than
59% of the 85 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.20 vs. ENZ: 33.02 )
Ranked among companies with meaningful P/E(ttm) only.
ENZ' s P/E(ttm) Range Over the Past 10 Years
Min: 26.02  Med: 199.81 Max: 1183.33
Current: 33.02
26.02
1183.33
PE(NRI) 33.71
ENZ's PE(NRI) is ranked lower than
58% of the 86 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.80 vs. ENZ: 33.71 )
Ranked among companies with meaningful PE(NRI) only.
ENZ' s PE(NRI) Range Over the Past 10 Years
Min: 26.62  Med: 194.82 Max: 887.5
Current: 33.71
26.62
887.5
P/B 4.30
ENZ's P/B is ranked lower than
66% of the 177 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.84 vs. ENZ: 4.30 )
Ranked among companies with meaningful P/B only.
ENZ' s P/B Range Over the Past 10 Years
Min: 0.85  Med: 2.97 Max: 7.13
Current: 4.3
0.85
7.13
P/S 2.06
ENZ's P/S is ranked higher than
63% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.78 vs. ENZ: 2.06 )
Ranked among companies with meaningful P/S only.
ENZ' s P/S Range Over the Past 10 Years
Min: 0.56  Med: 2.05 Max: 13.98
Current: 2.06
0.56
13.98
PFCF 20.91
ENZ's PFCF is ranked higher than
71% of the 68 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.57 vs. ENZ: 20.91 )
Ranked among companies with meaningful PFCF only.
ENZ' s PFCF Range Over the Past 10 Years
Min: 16.48  Med: 44.53 Max: 126.79
Current: 20.91
16.48
126.79
POCF 16.89
ENZ's POCF is ranked higher than
62% of the 88 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.31 vs. ENZ: 16.89 )
Ranked among companies with meaningful POCF only.
ENZ' s POCF Range Over the Past 10 Years
Min: 13.31  Med: 39.96 Max: 98.61
Current: 16.89
13.31
98.61
EV-to-EBIT 28.94
ENZ's EV-to-EBIT is ranked lower than
65% of the 101 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.06 vs. ENZ: 28.94 )
Ranked among companies with meaningful EV-to-EBIT only.
ENZ' s EV-to-EBIT Range Over the Past 10 Years
Min: -65.1  Med: -9.00 Max: 32.8
Current: 28.94
-65.1
32.8
EV-to-EBITDA 17.75
ENZ's EV-to-EBITDA is ranked lower than
64% of the 105 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 14.38 vs. ENZ: 17.75 )
Ranked among companies with meaningful EV-to-EBITDA only.
ENZ' s EV-to-EBITDA Range Over the Past 10 Years
Min: -62.3  Med: -11.30 Max: 76.5
Current: 17.75
-62.3
76.5
Current Ratio 2.05
ENZ's Current Ratio is ranked lower than
59% of the 191 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.68 vs. ENZ: 2.05 )
Ranked among companies with meaningful Current Ratio only.
ENZ' s Current Ratio Range Over the Past 10 Years
Min: 1.34  Med: 13.44 Max: 33.9
Current: 2.05
1.34
33.9
Quick Ratio 1.75
ENZ's Quick Ratio is ranked lower than
61% of the 191 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.41 vs. ENZ: 1.75 )
Ranked among companies with meaningful Quick Ratio only.
ENZ' s Quick Ratio Range Over the Past 10 Years
Min: 0.95  Med: 13.06 Max: 33.15
Current: 1.75
0.95
33.15
Days Inventory 52.88
ENZ's Days Inventory is ranked higher than
66% of the 153 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 88.26 vs. ENZ: 52.88 )
Ranked among companies with meaningful Days Inventory only.
ENZ' s Days Inventory Range Over the Past 10 Years
Min: 53.6  Med: 60.27 Max: 75.03
Current: 52.88
53.6
75.03
Days Sales Outstanding 47.56
ENZ's Days Sales Outstanding is ranked higher than
74% of the 155 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.71 vs. ENZ: 47.56 )
Ranked among companies with meaningful Days Sales Outstanding only.
ENZ' s Days Sales Outstanding Range Over the Past 10 Years
Min: 45.29  Med: 50.46 Max: 99.02
Current: 47.56
45.29
99.02
Days Payable 62.84
ENZ's Days Payable is ranked higher than
58% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 52.88 vs. ENZ: 62.84 )
Ranked among companies with meaningful Days Payable only.
ENZ' s Days Payable Range Over the Past 10 Years
Min: 29.17  Med: 54.37 Max: 64.59
Current: 62.84
29.17
64.59

Valuation & Return

vs
industry
vs
history
Price/Net Cash 54.88
ENZ's Price/Net Cash is ranked lower than
97% of the 66 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.08 vs. ENZ: 54.88 )
Ranked among companies with meaningful Price/Net Cash only.
ENZ' s Price/Net Cash Range Over the Past 10 Years
Min: 3.26  Med: 8.51 Max: 143
Current: 54.88
3.26
143
Price/Net Current Asset Value 7.84
ENZ's Price/Net Current Asset Value is ranked lower than
55% of the 113 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.80 vs. ENZ: 7.84 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ENZ' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.37  Med: 5.79 Max: 33.58
Current: 7.84
2.37
33.58
Price/Tangible Book 5.93
ENZ's Price/Tangible Book is ranked lower than
60% of the 156 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.14 vs. ENZ: 5.93 )
Ranked among companies with meaningful Price/Tangible Book only.
ENZ' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.97  Med: 5.06 Max: 29.77
Current: 5.93
1.97
29.77
Price/Median PS Value 1.00
ENZ's Price/Median PS Value is ranked lower than
57% of the 157 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.91 vs. ENZ: 1.00 )
Ranked among companies with meaningful Price/Median PS Value only.
ENZ' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.27  Med: 3.72 Max: 23.46
Current: 1
0.27
23.46
Price/Graham Number 2.99
ENZ's Price/Graham Number is ranked lower than
56% of the 94 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.37 vs. ENZ: 2.99 )
Ranked among companies with meaningful Price/Graham Number only.
ENZ' s Price/Graham Number Range Over the Past 10 Years
Min: 2.53  Med: 5.54 Max: 21.01
Current: 2.99
2.53
21.01
Earnings Yield (Greenblatt) (%) 3.46
ENZ's Earnings Yield (Greenblatt) (%) is ranked higher than
65% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. ENZ: 3.46 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ENZ' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 3.1  Med: 3.30 Max: 4.6
Current: 3.46
3.1
4.6
Forward Rate of Return (Yacktman) (%) 10.41
ENZ's Forward Rate of Return (Yacktman) (%) is ranked lower than
51% of the 57 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 11.03 vs. ENZ: 10.41 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
ENZ' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -31.2  Med: -1.60 Max: 16.7
Current: 10.41
-31.2
16.7

More Statistics

Revenue(Mil) $98
EPS $ 0.13
Beta1.01
Short Percentage of Float2.43%
52-Week Range $2.26 - 5.09
Shares Outstanding(Mil)46.07

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, IDXX » details
Traded in other countries:EZB.Germany,
Enzo Biochem Inc was founded in 1976. It is engaged in research, development, manufacturing and marketing of diagnostic and research products based on genetic engineering, biotechnology and molecular biology. The Company develops, manufactures and sells its proprietary technology solutions and platforms to clinical laboratories, specialty clinics and researchers and physicians. The Company's business segments are Enzo Clinical Labs, Enzo Life Sciences, and Enzo Therapeutics. The Enzo Clinical Labs is a clinical reference laboratory provides clinical services to a physicians, medical centers, other clinical labs and pharmaceutical companies. The Enzo Life Sciences manufactures, develops and markets products and tools to clinical research, drug development and bioscience research customers. Underpinned by broad technological capabilities, Enzo Life Sciences has developed proprietary products used in the identification of genomic information by laboratories around the world. The Enzo Therapeutics is a biopharmaceutical venture that has developed multiple novel approaches in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases, many of which are derived from the pioneering work of Enzo Life Sciences. It owns or license 245 patents relating to products, methods and procedures resulting from its internal or sponsored research projects. The Company distributes its life science products internationally through a network of distributors. It competes with other life science and biotechnology companies, as well as pharmaceutical, chemical and other companies. The Company is subject to licensing and regulation under federal, state and local laws relating to the handling and disposal of medical specimens, infectious and hazardous waste.
» More Articles for ENZ

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: BWEN, DDMG, ZHNE, ENZ, SIRO Nov 28 2011 
Weekly CFO Buys Highlight: BWEN, ENZ, PIP, HAFC, AACC Nov 21 2011 
Enzo Biochem Inc. Reports Operating Results (10-Q) Mar 14 2011 
Enzo Biochem Inc. Reports Operating Results (10-Q) Dec 10 2010 
Enzo Biochem Inc. Reports Operating Results (10-Q) Jun 09 2010 
Enzo Biochem Inc. Reports Operating Results (10-Q) Dec 10 2009 
Weekly Top Insider Buys: Bank of America Corp., Safeway Inc., Umpqua Holdings Corp., National Penn B Oct 24 2009 
Weekly Top Insider Buys: KB Home, National Penn Bancshares Inc., Moduslink Global Solutions Inc., En Oct 20 2009 
Enzo Biochem Inc. Reports Operating Results (10-Q) Sep 04 2009 
Enzo Biochem Inc. (ENZ) Files Quarterly Report for the Period Ended on 2008-10-31 Dec 15 2008 

More From Other Websites
ENZO Biochem Collects $7 Million From Court Approved Escrow Fund Closings Jan 26 2016
ENZO BIOCHEM INC Files SEC form 8-K, Other Events Jan 26 2016
Enzo Biochem Collects $7 Million from Court Approved Escrow Fund Closings Jan 26 2016
ENZO BIOCHEM INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jan 08 2016
ENZO Biochem Announces Patent Infringement Settlement with Agilent Technologies Jan 07 2016
ENZO BIOCHEM INC Files SEC form 8-K, Other Events Jan 06 2016
ENZO Biochem Updates Corporate Developments at Annual Shareholders Meeting Jan 06 2016
Enzo Biochem Updates Corporate Developments at Annual Shareholders Meeting Jan 06 2016
ENZO Biochem Reaches $9 Million Patent Infringement Settlement with Agilent Technologies, Inc.... Jan 06 2016
Enzo Biochem Reaches $9 Million Patent Infringement Settlement with Agilent Technologies, Inc. Jan 06 2016
ENZO BIOCHEM INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Dec 30 2015
Enzo Comments on Lone Star’s Decision to Withdraw Its Proxy Contest Dec 30 2015
Lone Star Value Issues Statement To Fellow Enzo Shareholders Dec 29 2015
ENZO BIOCHEM INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Dec 28 2015
ISS Endorses Enzo’s Nominees for Company’s Board of Directors Dec 28 2015
ENZO BIOCHEM INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Dec 23 2015
Glass Lewis Supports Enzo Nominees for Company’s Board of Directors Dec 23 2015
Enzo Biochem Issues Open Letter to Shareholders Dec 22 2015
Lone Star Value Issues Open Letter to Shareholders of Enzo Biochem, Inc. Dec 22 2015
ENZO BIOCHEM INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Dec 21 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK